title: Molecular MRI differentiation of VEGF receptor-2 levels in C6 and RG2 glioma models.
abstract: Vascular endothelial growth factor receptor 2 (VEGFR2) is an important angiogenic marker over-expressed in gliomas. With the use of molecular magnetic resonance imaging (mMRI) differing levels of VEGFR2 can be characterized in vivo with in rodent gliomas varying in angiogenesis. VEGFR2 levels were assessed by intravenous administration of an anti-VEGFR2 probe (anti-VEGFR2-albumin-Gd (gadolinium)-DTPA (diethylene triamine penta acetic acid)-biotin) into C6 or RG2 glioma-bearing rats, and visualized with mMRI. A non-specific IgG was coupled to the albumin-Gd-DTPA-biotin construct as a contrast agent molecular weight control. VEGFR2 levels are heterogeneous in different regions of C6 gliomas, whereas VEGFR2 was more homogenous or evenly distributed in RG2 gliomas. RG2 gliomas have less VEGFR2 within tumor periphery and peri-necrotic (p<0.05) regions, but more VEGFR2 within tumor interior regions (p<0.01), compared to C6 gliomas. mMRI results were confirmed with fluorescence staining and mean fluorescence intensity (MFI) quantification of the anti-VEGFR2 probe in excised glioma and brain tissues, as well as detection of VEGFR2 in C6 and RG2 gliomas and corresponding contalateral brain tissues. Ex vivo VEGFR2 levels were found to be significantly higher in C6 gliomas compared to RG2 tumors (p<0.001), which corresponded with in vivo detection using the VEGFR2 probe. Immunohistochemistry staining for HIF-1α (hypoxia inducible factor 1α), which is associated with angiogenesis, indicated higher levels in RG2 (p<0.01) compared to C6 gliomas. The data suggests that C6 gliomas have angiogenesis which is associated more with large blood vessels in tumor periphery and peri-necrotic regions, and less microvascular angiogenesis within the tumor interior, compared to RG2 gliomas.
authors.affiliation: Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation Oklahoma City, OK 73104 USA ; Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104 USA.
authors.forename: Ting
authors.initials: T
authors.lastname: He
authors.forename: Nataliya
authors.initials: N
authors.lastname: Smith
authors.forename: Debra
authors.initials: D
authors.lastname: Saunders
authors.forename: Benjamin P
authors.initials: BP
authors.lastname: Pittman
authors.forename: Megan
authors.initials: M
authors.lastname: Lerner
authors.forename: Stanley
authors.initials: S
authors.lastname: Lightfoot
authors.forename: Robert
authors.initials: R
authors.lastname: Silasi-Mansat
authors.forename: Florea
authors.initials: F
authors.lastname: Lupu
authors.forename: Rheal A
authors.initials: RA
authors.lastname: Towner
keywords: C6 and RG2 rat gliomas; Molecular magnetic resonance imaging (mMRI); fluorescence imaging; in vivo; vascular endothelial growth factor receptor 2 (VEGFR2)
references.citation: Am J Pathol. 2005 Oct;167(4):1161-72
references.pmid: 16192650
references.citation: Cancer Res. 2003 Sep 15;63(18):5838-43
references.pmid: 14522907
references.citation: J Am Chem Soc. 2010 Sep 22;132(37):12829-31
references.pmid: 20795620
references.citation: Glia. 1995 Nov;15(3):339-47
references.pmid: 8586468
references.citation: NMR Biomed. 2002 Apr;15(2):120-31
references.pmid: 11870908
references.citation: Endocr Rev. 2004 Aug;25(4):581-611
references.pmid: 15294883
references.citation: J Neurooncol. 1998 Jan;36(1):91-102
references.pmid: 9525831
references.citation: Free Radic Biol Med. 2010 Mar 1;48(5):691-703
references.pmid: 20034558
references.citation: Eur J Cancer. 1996 Dec;32A(14):2534-9
references.pmid: 9059344
references.citation: J Magn Reson Imaging. 2010 Aug;32(2):267-75
references.pmid: 20677250
references.citation: Cancer Cell. 2008 Mar;13(3):206-20
references.pmid: 18328425
references.citation: Mol Cancer Ther. 2006 Nov;5(11):2624-33
references.pmid: 17121909
references.citation: Adv Genet. 2010;69:1-30
references.pmid: 20807600
references.citation: Angiogenesis. 2010 Jun;13(2):71-4
references.pmid: 20559867
references.citation: Front Biosci. 2007 May 01;12:4267-79
references.pmid: 17485373
references.citation: J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S
references.pmid: 18523069
references.citation: Lab Invest. 2006 Dec;86(12):1221-32
references.pmid: 17075581
references.citation: Neoplasia. 2001 Mar-Apr;3(2):143-53
references.pmid: 11420750
references.citation: Magn Reson Med. 2010 Aug;64(2):369-76
references.pmid: 20665780
references.citation: Free Radic Biol Med. 2008 Jan 1;44(1):63-72
references.pmid: 18045548
references.citation: J Neurooncol. 2009 Sep;94(3):299-312
references.pmid: 19381449
references.citation: Cancer. 2002 Feb 1;94(3):738-45
references.pmid: 11857307
references.citation: Science. 1968 Jul 26;161(3839):370-1
references.pmid: 4873531
references.citation: Lab Invest. 2006 Jun;86(6):599-609
references.pmid: 16607378
references.citation: Radiology. 2007 Aug;244(2):449-56
references.pmid: 17562810
references.citation: J Clin Oncol. 2006 Jan 1;24(1):16-24
references.pmid: 16330672
references.citation: J Cell Mol Med. 2011 Apr;15(4):837-49
references.pmid: 20497492
references.citation: Cell Tissue Res. 2002 Dec;310(3):257-70
references.pmid: 12457224
references.citation: Nat Med. 2003 Jun;9(6):713-25
references.pmid: 12778170
references.citation: Free Radic Biol Med. 2011 Jul 15;51(2):490-502
references.pmid: 21600283
references.citation: J Cereb Blood Flow Metab. 2009 Oct;29(10):1714-26
references.pmid: 19584891
references.citation: NMR Biomed. 2008 Nov;21(10):1043-56
references.pmid: 18615861
references.citation: Arterioscler Thromb Vasc Biol. 1996 Nov;16(11):1399-405
references.pmid: 8911280